JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock, valued at approximately $7,901,824. JPMorgan Chase & Co. (NYSE:JPM) stock performance was 0.84% in last session and finished the day at $55.26. Traded volume was 27.05million shares in the last session and the average volume of the stock remained 20.13million shares. The beta of the stock remained 1.71. JPMorgan Chase & Co. (NYSE:JPM) insider ownership is 0.10%.

Micron Technology Inc (NYSE:MU) CEO Dermot Mark Durcan sold 200,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $21.90, for a total value of $4,380,000.00. Micron Technology, Inc. (NASDAQ:MU) rose 1.40 percent to $22.48 Wednesday on volume of 21.62million shares. The intra-day range of the stock was $22.00 to $22.57. Micron Technology, Inc. (NASDAQ:MU) has a market capitalization of $24.06billion.

Gilead Sciences Inc (NASDAQ:GILD) EVP Norbert W. Bischofberger sold 90,000 shares of the stock on the open market in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $67.03, for a total transaction of $6,032,700.00. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on Apr 16, 2014 reported a increase of 1.63% to the closing price of $69.28. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $106.54billion. The overall volume in the last trading session was 17.27million shares. In its share capital, GILD has 1.54billion outstanding shares.

Arena Pharmaceuticals Inc (NASDAQ:ARNA) Director Tina Susan Nova sold 35,000 shares of Arena Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $6.22, for a total transaction of $217,700.00. Following the sale, the director now directly owns 18,728 shares of the company’s stock, valued at approximately $116,488. On Wednesday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -0.79% to close the day at $6.30. Company return on investment (ROI) is -1390% and its monthly performance is recorded as -4.55%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is -13.82%.